DTech Liquidating

DTech Liquidating Diluted EPS

Delisted

The Diluted Earnings per Share of DTech Liquidating (DMTKQ) as of Nov 21, 2026 is -3.09 USD. In the previous year, Diluted Earnings per Share was -3.88 USD — a change of -20.34% (higher).

Diluted EPS

-3.09USD

YoY

-20.34%

Last updated:

Diluted Earnings per Share of DTech Liquidating is 2023 -3.09 USD. Diluted Earnings per Share of DTech Liquidating was 2022 -3.88 USD. It decreases by -20.34% higher compared to the previous year.

The DTech Liquidating Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2016
0.00 USD
Jan 1, 2017
-0.05 USD
Jan 1, 2018
0.14 USD
Jan 1, 2019
-2.81 USD
Jan 1, 2020
-2.15 USD
Jan 1, 2021
-2.71 USD
Jan 1, 2022
-3.88 USD
Jan 1, 2023
-3.09 USD
The DTech Liquidating Diluted EPS history
YEARDiluted EPSYoY
-3.09USD-20.34%
-3.88USD+43.17%
-2.71USD+26.05%
-2.15USD-23.49%
-2.81USD-2,107.14%
0.14USD-380.00%
-0.05USD—
0.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DTech Liquidating Stock analysis

What does DTech Liquidating do? DermTech, Inc. develops and sells non-invasive genomics tests for skin disease diagnosis and treatment, focusing on melanoma detection. The company's primary product, the DermTech Melanoma Test (DMT), marketed as Pigmented Lesion Assay (PLA), analyzes skin samples collected via Smart Stickers to identify genomic markers linked to melanoma. Healthcare providers and dermatologists purchase these tests to assess pigmented skin lesions, addressing unmet needs in diagnosing melanoma early. The company's technology enables non-invasive early detection of higher-risk lesions, reducing unnecessary biopsies. DermTech's commercial test targets the diagnostic pathway for pigmented skin lesions, commonly known as moles, which are dark-colored patches of skin. The firm's focus on inflammatory skin diseases and aging-related skin conditions complements its melanoma detection offerings. By enhancing early melanoma detection through genomic analysis, DermTech provides a solution for clinicians managing skin cancer risks without invasive procedures. The company's products are designed to facilitate clinical assessment of skin lesions that raise melanoma concerns, streamlining the diagnostic process. DermTech's approach to non-invasive testing supports healthcare systems by improving efficiency in skin cancer management. The firm's technology specifically addresses genomic markers associated with melanoma, offering a targeted solution for high-risk lesion identification. DTech Liquidating is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DTech Liquidating stock

Diluted Earnings per Share of DTech Liquidating is -3.09 USD in 2023.

Diluted Earnings per Share of DTech Liquidating changed from -3.88 USD to -3.09 USD, representing a -20.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share DTech Liquidating since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — DTech Liquidating

All Key Metrics — DTech Liquidating